National Academies Press: OpenBook

Making Medicines Affordable: A National Imperative (2018)

Chapter: Appendix D: Stakeholder Input

« Previous: Appendix C: Glossary
Suggested Citation:"Appendix D: Stakeholder Input." National Academies of Sciences, Engineering, and Medicine. 2018. Making Medicines Affordable: A National Imperative. Washington, DC: The National Academies Press. doi: 10.17226/24946.
×

D

Stakeholder Input

RASHMI AGARWAL, U.S. Government Accountability Office

PETER BACH, Memorial Sloan Kettering Cancer Center

DAVID BEIER, Bay City Capital

ERNST BERNDT, Massachusetts Institute of Technology Sloan School of Management

GAIL CASSELL, Infectious Disease Research Institute; formerly, Eli Lilly and Company

RON COHEN, Acorda Therapeutics; Biotechnology Industry Organization

NITIN DAMLE (Co-Sponsor), American College of Physicians

GWEN DARIEN, National Patient Advocate Foundation

JOSEPH DIMASI, Tufts Center for the Study of Drug Development

AUTUMN EHNOW, Medicines360

MARIA FREIRE, Foundation for the National Institutes of Health; United Nations High-Level Panel on Access to Medicines

STEVEN GALSON, Amgen

ROBERT GALVIN, Equity Healthcare, Blackstone Group

JEREMY GREENE, Johns Hopkins University School of Medicine

KEVIN GRIMES, Stanford School of Medicine

RONALD HANSEN, University of Rochester Simon Business School

AARON KESSELHEIM, Brigham and Women’s Hospital

CHRISTOPHER KOLLER (Co-Sponsor), Milbank Memorial Fund

SHARON LEVINE, Kaiser Permanente Medical Group

FREDA LEWIS-HALL, Pfizer Inc.

FRANK LICHTENBERG, Columbia University

Suggested Citation:"Appendix D: Stakeholder Input." National Academies of Sciences, Engineering, and Medicine. 2018. Making Medicines Affordable: A National Imperative. Washington, DC: The National Academies Press. doi: 10.17226/24946.
×

ANDREW LO, Massachusetts Institute of Technology Sloan School of Management

STACIE MAASS, American Pharmacists Association

STEVE MILLER, Express Scripts

JENNIFER MOORE, Institute for Medicaid Innovation

LARRY NORTON (Co-Sponsor), Breast Cancer Research Foundation

DAVID PARKINSON, Essa Pharmaceuticals

HAROLD PAZ, Aetna

STEVEN PEARSON, Institute for Clinical and Economic Review

GEORGE POSTE, Arizona State University

BRUCE RECTOR, Doctors for America

JOHN ROTHER, National Coalition on Health Care

DAVID SCHLEIFER, Public Agenda

KEVIN SCHULMAN, Duke University School of Medicine

SUSAN STUARD, Oregon Health & Science University

MASON TENAGLIA, QuintilesIMS Institute

ROY VAGELOS, Regeneron Pharmaceuticals, Inc.; formerly, Merck & Co., Inc.

CHRISTOPHER VIEHBACHER, Boston Pharmaceuticals; formerly, Sanofi

HAIME WORKIE, Financial Industry Regulatory Authority

Suggested Citation:"Appendix D: Stakeholder Input." National Academies of Sciences, Engineering, and Medicine. 2018. Making Medicines Affordable: A National Imperative. Washington, DC: The National Academies Press. doi: 10.17226/24946.
×
Page 189
Suggested Citation:"Appendix D: Stakeholder Input." National Academies of Sciences, Engineering, and Medicine. 2018. Making Medicines Affordable: A National Imperative. Washington, DC: The National Academies Press. doi: 10.17226/24946.
×
Page 190
Next: Appendix E: Biographical Information »
Making Medicines Affordable: A National Imperative Get This Book
×
Buy Paperback | $65.00 Buy Ebook | $54.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicines—and health care at large—more affordable for everyone has become a socioeconomic imperative.

Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual’s insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugs—coupled with the broader trends in overall health care costs—is unsustainable to society as a whole.

Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!